Hypothermic circulatory arrest (HCA) provides neuroprotection during cardiac surgery but entails an ischemic period that can lead to excitotoxicity, neuroinflammation, and subsequent neurologic injury. Hydroxyl polyamidoamine (PAMAM) dendrimers target activated microglia and damaged neurons in the injured brain, and deliver therapeutics in small and large animal models. We investigated the effect of dendrimer size on brain uptake and explored the pharmacokinetics in a clinically-relevant canine model of HCA-induced brain injury. Generation 6 (G6,~6.7 nm) dendrimers showed extended blood circulation times and increased accumulation in the injured brain compared to generation 4 dendrimers (G4,~4.3 nm), which were undetectable in the brain by 48 h after final administration. High levels of G6 dendrimers were found in cerebrospinal fluid (CSF) of injured animals with a CSF/serum ratio of~20% at peak, a ratio higher than that of many neurologic pharmacotherapies already in clinical use. Brain penetration (measured by drug CSF/serum level) of G6 dendrimers correlated with the severity of neuroinflammation observed. G6 dendrimers also showed decreased renal clearance rate, slightly increased liver and spleen uptake compared to G4 dendrimers. These results, in a large animal model, may offer insights into the potential clinical translation of dendrimers.
Introduction
Hypothermic circulatory arrest (HCA) provides neuroprotection during complex cardiac surgical operations that require partial or complete interruption of the cerebral circulation. These include certain procedures involving repair or replacement of the aortic arch, as well as congenital heart surgery [1] [2] [3] [4] . Despite these advances, HCA continues to be associated with neurological sequelae in both pediatric and adult patients [4, 5] . For over 20 years, Baumgartner and colleagues have utilized a model of HCA in large canine subjects. This technique involves peripheral cannulation for cardiopulmonary bypass (CPB), followed by systemic cooling on CPB to 18°C, at which point canines are subjected to a 60-120 min' period of HCA followed by rewarming and resuscitation ( Fig. 1) . Glutamate-mediated excitotoxicity [6, 7] and neuroinflammation [8] are major pathological mechanisms that lead directly to brain injury in the hippocampus, cortex, basal ganglia and cerebellum in this model [9] [10] [11] [12] . Accordingly, to mitigate excitotoxicity and neuroinflammation, therapeutics should be delivered to injured neurons and activated glial cells in injured brain regions [12] . Unfortunately, current therapeutic interventions have not yet shown significant efficacy in improving neurological outcomes. This is due in part to the limited ability of small drug molecules to cross the blood-brain barrier (BBB), resulting in relatively poor accumulation in the central nervous system (CNS) and cerebrospinal fluid (CSF). Free drug therapies also expose patients to the risk of drug toxicity at higher doses [13] [14] [15] .
We have demonstrated that hydroxyl-terminated generation 4 polyamidoamine (PAMAM) dendrimers (G4 dendrimers) provide sitespecific delivery of small molecular drugs across the BBB and blood-CSF barriers, specifically targeting the injured brain in this canine HCA model [12] . However, greater brain accumulation and enhanced CSF penetration could be beneficial for translating dendrimer-based therapies from animal studies to humans, where dose and toxicity concerns are paramount. G4 dendrimers, though able to specifically target injured brain regions in our canine HCA model, have rapid systemic clearance in many species, including canine [12] , rabbit [16] , rat [17] , and mouse [18] . Such rapid clearance limits dendrimer accumulation in injured brain regions. In this study, we tested the hypothesis that the use of larger size dendrimers would enhance dendrimer accumulation in the brain due to delayed clearance and prolonged systemic circulation while maintaining their intrinsic targeting ability to activated microglia and injured neurons.
Plasma-binding properties and nanoparticle size are the two dominating factors that define in vivo clearance rate and secretion pathway. Nanoparticles that have a hydrophobic surface or charged surface properties are more likely to interact and bind with plasma proteins during systemic circulation, and to induce opsonization that leads to elevated reticuloendothelial system (RES) clearance and increased liver uptake [19, 20] . G4 dendrimers, which have a neutral surface charge, have fewer interactions with key human plasma proteins in vitro [21] , and are generally considered as non-plasma binding nanoparticles. For these nanoparticles, particles size plays the primary role in determining the mode of clearance [22] . The upper limit for effective glomerular filtration lies between 6 and 8 nm [20] . In general, nanoparticles can be cleared efficiently by renal glomeruli at diameters below this range. Alternatively, nanoparticles larger than this range are less likely to be cleared through renal filtration [23] . These nanodevices, if not dissociable or degradable rapidly, tend to be cleared by the reticuloendothelial system (RES) and are cleared by the liver [20] .
Generation 6 (G6) dendrimers with hydroxyl terminal groups have a hydrodynamic diameter around 6.7 nm (~1.5-fold higher than G4 dendrimers) and provide similar surface properties as G4 dendrimers (neutral and hydrophilic). Like the G4 dendrimer, they are unlikely to bind with serum proteins in the plasma. However, the G6 dendrimer's size lies on the edge of the renal filtration range; therefore, this slight increase in size can potentially extend the circulation period after systemic dendrimer administration without altering the major renal clearance pathway.
In this study, we determined the pharmacokinetics of G6 dendrimers in a clinically relevant large animal model, with a focus on 1) how the G6 dendrimer's increased size affects its systemic circulation time and clearance pathway, and 2) whether these changes in biodistribution profiles can enhance the targeting characteristics in the injured brain as compared to the G4 dendrimer (G4 dendrimer data was obtained from our previous experiments in this canine model [12] ). The comparison of pharmacokinetics and biodistribution of G6 dendrimers with G4 dendrimers may offer clinical insight and significance in translating dendrimer research into human trials.
Materials and methods
Synthesis of G6-Cy5. The synthesis (Fig. 1A) , characterization ( Fig. S1-4) , and purification of G6-Cy5 were based on our previously published work for labeling G4 PAMAM dendrimers [12] . All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless further noted. In an oven-dried round bottom flask, 6-Fmoc-capronic acid (100 mg, 0.283 mmol), PyBOP (216 mg, 0.415 mmol; Bachem, Torrance, CA), and N,NDiisopropylethylamine (DIEA) (100 μL, 0.574 mmol) were combined and dissolved in anhydrous Dimethylformamide (DMF) (15 mL) under N 2 gas environment. This reaction mixture was stirred at 0°C for 15 min. This solution was then combined with generation 6 hydroxyl-terminated PAMAM dendrimer (1.100 g, 0.01887 mmol; Dendritech, Inc., Midland, MI) that was initially dissolved in anhydrous DMF (25 mL). The reaction was continued for 48 h at room temperature. The solution was then concentrated in vacuo for 20 min to remove DMF and DIEA, with temperature maintained at around 25°C during this process. To proceed for dialysis, concentrated reaction mixture was redissolved in~100 mL of DMF and was dialyzed against 2 L of DMF for 24 h (Molecular weight cutoff (MWCO): 8 kD), with dialysis solvent replaced every 8-12 h. The dialyzed solution was then concentrated under reduced pressure and dried over high vacuum to yield the first intermediate. To proceed with Fmoc deprotection, this crude material was then dissolved in anhydrous DMF (5 mL) and mixed with piperidine/DMF (1:4; 10 mL) in ice bath for 15 min. The reagents were then removed under reduced pressure until dry. The residue was then redissolved in DMF and then dialyzed against DMF (MWCO: 8kD) for 24 h. The dialyzed solution was then concentrated in vacuo, redissolved in DI H 2 O, and dialyzed against DI H 2 O for 2 h. The obtained aqueous solution was then lyophilized to yield the dry mass of bifunctional dendrimer G6-(OH) 249 -(NH 2 ) 7 . The bifunctional dendrimer (200 mg) was dissolved in anhydrous DMF (4 mL), which was later mixed with triethylamine (100 μL) and Cy5-mono-NHS ester (10 mg; GE Healthcare, Pittsburgh, PA) that was dissolved in anhydrous DMSO (2 mL). The reaction was carried out overnight and then concentrated under reduced pressure. The residue was redissolved in DMF and dialyzed against DMF (MWCO: 8kD) for 48 h. The dialyzed solution was concentrated, re-dissolved in H 2 O, and then dialyze against H 2 O (MWCO: 8 kD) for 2 h. The dialyzed solution was then lyophilized to give dry solids. The final conjugates were characterized by 1 H NMR (Fig. S1 ), RP-HPLC (Fig. S2 ), and fluorospectroscopy ( Fig. 1B and Fig. S3 ). Surgical procedure of hypothermic cardiac arrest and dendrimer administration.
The canine model of HCA used is described previously [9] . Class-A 30 kg male hounds, 6-12 months old, were used in this study. Experimental approval was obtained from the Johns Hopkins University Animal Care and Use Committee (D0313M06) and all relevant members of the surgical and care teams underwent appropriate training prior to initiation of the study. The dogs were anesthetized with methohexital sodium (12 mg/kg i.v., in divided doses) and maintained on isoflurane inhalational anesthesia, i.v. fentanyl (150-200 μg/dose), and midazolam (2.5 mg/dose) following endotracheal intubation. Temperature probes were placed in the ear (tympanic membrane), esophagus, and rectum for the duration of the experiment. A left femoral arterial pressure catheter also was placed for continuous monitoring of blood pressure and arterial blood sampling. Continuous electrocardiographic monitoring was employed.
All dogs were given a total dose of 6 mg/kg G6-Cy5; the dendrimers were dissolved in sterile saline, followed with immediate filtration through membrane of 0.4 μm pore size prior to the administration. The G6-Cy5 was administered as three separate doses prior to and post HCA (Fig. 1C) . Initially, 10% of the total G6-Cy5 dose was administered as an intravenous bolus on the morning of surgery prior to initiation of CPB. Animals were then heparinized and peripherally cannulated for CPB with one femoral arterial cannula (advanced into the descending thoracic aorta) as well as femoral and external jugular venous cannulae (advanced through the inferior and superior vena cavae, respectively, into the right atrium). The animals were cooled to 18°C, and then underwent 90 min of HCA with standard hemodilution and alpha-stat regulation of arterial blood gases. After HCA, CPB was reinstituted, the animal was rewarmed (5°C/15 min) to 37°C, and subsequently 70% of the overall G6-Cy5 dose was infused over a 6 h time span. The CPB cannulae were then removed, hemostasis achieved, and heparinization was reversed with protamine (3 mg/kg). After canines were hemodynamically and clinically stable, the animals were transferred to a cage for recovery and provided with analgesia as needed. An additional bolus dose (20% of total dose) was given at 24 h after the HCA procedure (i.e., morning of postoperative day 1). At 72 h after HCA (48 h after the last dendrimer administration), the animals were anesthetized, intubated, and maintained on inhalational agents. A median sternotomy was performed followed by proximal aortic cannulation. Cold saline was then infused via an aortic cannula, and the animals were exsanguinated into the thorax. Major organs (brain, heart, lung, liver, kidney, pancreas, spleen) were collected and snap frozen for biodistribution analysis. To evaluate dendrimer pharmacokinetics, CSF (~100 μL), serum (~500 μL) and urine (5-10 mL) were collected at representative time points during the whole experiment. Slow intravenous infusion of normal saline was performed after CSF and blood draw for volume correction.
G6-Cy5 extraction and quantification of G6-Cy5 in biofluids and tissues.
Dendrimer extraction and quantification followed previous protocols [12] . For liquid samples (such as serum, urine or CSF), the fluid was directly diluted with DPBS at least 10-fold to fit into the linear detection range of our spectrofluorophotometer (Shimadzu RF5301-PC, Shimadzu Scientific Instrument Inc. USA, Columbia, MD). Fluorescence intensities were converted to G6-Cy5 concentration using calibrated samples of known concentrations of G6-Cy5. For tissue samples, approximately 100 mg of tissue was sliced from each organ and then homogenized by a bullet blender for 10 min. The homogenized tissue then was mixed with 1 mL MeOH per 100 mg of tissue, vortexed, and bath sonicated for 10 min to give a cloudy suspension that later was centrifuged at 15000 rpm (14.4 rpm) for 15 min at 4°C to separate the tissue precipitates and supernatant. As above, fluorescent intensities were converted to levels of G6-Cy5 using a G6-Cy5 calibration curve in MeOH. All calibration curves exhibited high linearity with R
2~0
.99. For dendrimer extraction, the recovery rate was higher than 95%.
Immunofluorescence staining. Slices (1 to 2 mm) of freshly harvested hippocampal tissue were fixed by immersion in 4% neutral buffered formalin for 8 h followed by cryoprotection in graded sucrose solutions. Cryostat sections (30 μm) were processed for immunohistochemical detection of microglia/macrophages (rabbit anti-Iba1, Wako Laboratory Chemicals #019-19,741, 1:2000, overnight at 4°C), astrocytes (rabbit anti-GFAP, Dako Z0334, 1:5000, overnight at 4°C), or neurons (mouse anti-beta III tubulin-Alexa Fluor® 488, Abcam #169556, 1:600, 4 h at RT). Rabbit primary antibodies were detected using goat-anti-rabbit-Alexa Fluor® 488 (LifeTechnologies, 1:500, 1 h at RT). A DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride) nuclear counterstain was used to delineate neuroanatomic regions. Coverslips were mounted using Dako fluorescence anti-fade mounting media.
Confocal microscopy study of G6 dendrimer distribution in brain, kidney, liver, and spleen.
Stained tissue sections were imaged under a confocal LSM 710 microscope (Carl Zeiss; Hertfordshire, UK) and processed by ZEN 2011 software. Imaging settings were optimized for each organ or cell type to observe G6-Cy5 localization within microglia, neurons, and astrocytes in the brain, or for G6-Cy5 distribution in the kidney, liver, and spleen. To compare G4 and G6 dendrimers distribution, all imaging settings including laser index, pinhole size, gain, imaging speed, and image quality were kept consistent across all animals.
Results and discussion
The prolonged circulation of G6 PAMAM dendrimer in serum. We evaluated the in vivo stability of G6-Cy5 by RP-HPLC analysis of serum samples acquired at different time points after G6-Cy5 administration ( Fig. S4 A-I) . A fluorescence detector (λ ex = 645 nm, λ em = 660 nm) and the photodiode array (PDA) was used to detect G6-Cy5 and free Cy5 (Fig. S4 A and B) in all collected samples. G6-Cy5 was detected in all serum samples (Fig. S4 B, C, D) , and the UV spectrum of eluted dendrimers from all serum samples (Fig. S4 G, H, I ) had the same pattern as standard G6-Cy5 (Fig. S4 E, F) , though there was a slight delay in retention time (0.6 min delay compared with the standard G6-Cy5 sample) (Fig. S4 B) . None of the tested serum samples contained free Cy5, as compared with the standard free Cy5 peak. Quantifications of dendrimer levels in biofluids/tissues were based on the fluorescence intensity of G6-Cy5 measured at the emission peak (662 nm) (see Fig.  1B for the fluorescence spectra).
In this experiment, we used a dosing regimen that differed from the G4 dendrimer experiment (which was simply a 1 h i.v. infusion after HCA). The current administration protocol of G6 dendrimers in our canine HCA model was designed to be more clinically relevant and, potentially, to address injury as it occurred. We administered 10% of the total dose as a bolus at 3 h prior to the conclusion of HCA and infused 70% of the total dose between 0 and 6 h immediately after HCA (Fig. 1C) . At 24 h after HCA, the remaining 20% of the total dose was injected as a bolus. This regimen allows the G6 dendrimers to pre-circulate in the blood before the HCA-induced injury increases BBB permeability. Therefore, we hoped that already-circulating dendrimers would guarantee rapid dendrimer arrival to foci of injury.
Although the dosing regimens used to deliver G4 and G6 dendrimers differed, both G4 and G6 dendrimer doses were completely administrated by 47 h prior to the experiment's conclusion. Therefore, the dendrimer concentration during the last 47 h of each experiment should be a reasonable window to compare the systemic circulation of G4 and G6 dendrimers. In general, the G6 dendrimer levels in the serum rose during the dendrimer infusion (0-6 h after HCA), peaking at around 6-7 h after HCA and then plummeting before the second bolus dose that was given at 24 h after HCA ( Fig. 2A) . During the following 6 h after the second bolus, G6 dendrimers level in serum hovered around 28-36% of cumulative dose (dose being administered at the time of evaluation; the calculation was based on a 30 kg dog, and the serum volume was estimated to be~1400 mL) [24] . The concentration of G6 dendrimers gradually decreased afterwards to~17.4% of cumulative dose at 72 h after HCA among the 4 monitored animals. In our previous study of the canine HCA model, G4 dendrimers were able to remain in the serum at a concentration of 7.04 μg/mL at 47 h post infusion, which was 6.5% of total dose [12] . Our results for G6 dendrimers showed that a higher percentage of the ID (17.4%) was present in the serum at a later longer time point (66 h after 80% of the total dose was given; 48 h after the total dose was given than the G4 dendrimer). This 17.4% represents over twice the percentage of that seen for G4 dendrimers, suggesting that G6 dendrimer circulation time was longer than that for G4 dendrimers in this canine model. G6 dendrimers show enhanced CSF partition and brain uptake in HCA dogs.
To assess the G6 dendrimer's CNS penetration, we measured G6 dendrimer CSF levels at various time points. The G6 dendrimer concentrations in CSF were normalized by their respective concentrations in the serum (Fig. 2B) . Among the four animals, CSF/serum ratio varied: animals 1 and 2 demonstrated overall higher CSF/serum ratios than animals 3 and 4. After the first bolus dose (10% of total dose) and during the 6 h of G6 dendrimer infusion (70% of total dose), the CSF/serum ratio for animals 1 and 2 reached 0.2-0.4. At the end of the experiment (48 h after the last dose; hour 75), the CSF/serum ratio for animal 1 and 2 was approximately 0.04. For animals 3 and 4, the CSF/serum ratios were around 0.02-0.002 throughout the whole experiment. To further assess these differences, we measured the accumulation of G6 dendrimers in different brain regions (Fig. 2C) . At 48 h after the last dose of G6-Cy5 (72 h after HCA), G6 dendrimer accumulation was highest in the hippocampus followed by cerebellum and then the cortex (mean values were 129 ± 56 ng/g in hippocampus, 116 ± 22 ng/g in cerebellum and 68 ± 16 ng/g in cortex (Fig. 2C) . G6 dendrimer accumulation in hippocampus, the most injured region, was most closely correlated with the CSF/serum ratio in each animal.
The CSF/serum ratio for G6 dendrimers ranged from 0.02-0.20 (on average) during the entire monitoring period, which is close to several common neuroactive agents (leptin, morphine, phenobarbital) after repetitively dosed to patients on daily bases [25, 26, 27] . When evaluating area under the curve (AUC) to determine the profile of CSF/serum ratios over time, the AUC of G6 dendrimers is also higher than several clinically used antibiotics, such as penicillin, cloxacillin, amoxicillin, piperacillin, clavulanatem, and cephalosporins (data not shown) [28] . Most systemically administrated drugs or blood-derived proteins have very limited CSF penetration ability, as the trafficking of molecules from blood to the CSF is restricted by selective permeation at the blood-CSF barrier [28] . In normal physiology, tight junctions between endothelial cells maintain the integrity of the blood-CSF barrier. However, the blood-brain barrier (BBB) is disrupted after HCA [7, 12, 29, 30] , which creates an opportunity for nanoparticles to enter the brain parenchyma. Although the precise size of blood-CSF barrier leakage in the HCA-induced brain injury is unclear in this model, our results suggest that crossing of the BBB is facilitated by the hydroxyl-terminated PAMAM dendrimers' sub-10 nm size and neutrally-charged surface properties.
PAMAM dendrimers also have been observed to cross the BBB in other CNS disease models, including ischemia/reperfusion injury [31] , ischemia-induced white matter injury [32] , cerebral palsy [16] , and brain tumors [17, 33] . However, the size chosen could still impact the accumulation level in the CSF and brain parenchyma. In this study, G6 dendrimers have a hydrodynamic diameter of 6.7 ± 0.6 nm, which is small enough to penetrate the disrupted blood-CSF barrier, but also to allow for longer systemic circulation compared to G4 dendrimers (~4.3 nm). Moreover, in the presence of inflammation, CSF outflow may decrease, leading to a reduction of CSF production and absorption rates that also increase the retention of G6 dendrimers in the CSF.
The accumulation of G6 dendrimers in brain tissue at 48 h after final bolus dose was much higher than that of G4 dendrimers at both 6 h post i.v. infusion (~30 ng/g in hippocampus,~10 ng/g in cortex, and~60 ng/g in cerebellum) and 24 h post i.v. infusion (undetectable at all 3 brain regions, detection limit~10 ng) (Fig. 2C ). In addition, the decreased duration of HCA (1.5 h, as compared to 2.0 h for the G4 dendrimer study) in the present study would be expected to cause less BBB impairment and decreased dendrimer brain penetration. Nonetheless, we observed a higher brain accumulation ratio for G6 versus G4 dendrimers. Although other differences existed between the two studies in terms of injection dose, severity of brain injury, and dosing regimen (Table 1) , G6 dendrimers showed 10-fold higher brain accumulation 48 h after injection of the last dose compared to G4 dendrimers 47 h after 1 h i.v. infusion. These data indicate that G6 dendrimers have enhanced brain uptake compared to G4 dendrimers. In consideration of the experimental ethics and expenses involved in large animal studies, we made a small modification of the protocol (the HCA time, and dosing regimen) in the G6 dendrimers experiment (Table 1) . However, the results from two experiments are still comparable at selected time points. The comparison of pharmacokinetics and biodistribution of G6 dendrimers with G4 dendrimers may offer significant insights into their payload delivery differences, which may be critical in clinical translation.
CNS penetration of G6 dendrimers is associated with the severity of CNS inflammation.
Although all HCA animals in this study demonstrated enhanced CSF penetration and brain uptake, the extent of CSF partition and brain uptake varied among animals. Recent review pointed out the connections between hallmarks of CNS inflammation (BBB impairment, microglia/ macrophage activation) and nanoparticles uptake by the CNS cells [34] . Here, we compared the extent of neuroinflammation among these animals by measuring interleukin 6 (IL-6) and interleukin 8 (IL-8) levels in the CSF at different time points. IL-6 and IL-8 concentrations in the CSF peaked 4-8 h after HCA (Fig. 3) , during the period when G6 dendrimers were infused intravenously and serum G6-Cy5 levels were maximal. The peak concentrations of IL-6 and IL-8 varied among the 4 animals, indicating that CNS inflammation varied after the 90-min HCA procedure. Interestingly, we found the peak concentrations of IL-6 and IL-8 among the 4 HCA animals followed the same trend (Animal 1 N Animal 2 N Animal 3 N Animal 4) as their respective dendrimer CSF/serum ratios and dendrimer hippocampal accumulations. There was a strong correlation between the peak CSF concentration of IL-6 (R 2 = 0.91) and IL-8 (R 2 = 0.95) and the dendrimer CSF/serum ratio after all G6 dendrimers were administered (24 h after HCA) among the 4 animals (Fig. S5 ). Although our sample size was limited in this study, this trend suggests that the ability of G6 dendrimers to cross the BBB correlated directly with the extent of CNS inflammation. G6 dendrimers selectively accumulate in the injured hippocampus.
The hippocampus is the most severely injured brain region in this HCA model [9] . Glutamate-induced excitotoxicity causes cell death in the hippocampus [35] , while ischemia-reperfusion injury contributes to early microglial activation in the hippocampus [36] . Our prior histological analyses of the hippocampus demonstrated that neuronal death occurred primarily by apoptosis in the dentate gyrus and by necrosis in the CA (Cornu Ammonis) region [37] . Of the three major regions of the hippocampus (dentate gyrus, CA1, and CA3) examined by confocal microscopy in this study, the dentate gyrus showed the greatest uptake of G6 dendrimer, followed by CA1 and CA3 regions (Fig. 4A-D) . In the dentate gyrus, G6 dendrimers were scattered in deeper regions of the granule cell layer where more injured neurons are found (Fig. 4D) . In the CA1 and CA3 regions, G6 dendrimers accumulated within necrotic neurons and within the walls of blood vessels in presumed endothelial cells (Fig. 4B-C) .
G6 dendrimer uptake is associated with cell types in hippocampal sub-regions.
Since the G6 dendrimer distribution showed different patterns of uptake in the dentate gyrus, CA1, and CA3, we used immunohistochemistry to classify the cell types taking up dendrimer. We used antibodies directed against Iba1 to identify microglia (Fig. 5A ), TUJ1 to identify neurons (Fig. 5B) , and GFAP to identify astrocytes (Fig. S6) . G6 dendrimers were localized in many microglial cells in the dentate gyrus; they were found within the microglial cell bodies and processes, as clustered foci (Fig. 5A) .
Neurons exhibited less frequent G6 dendrimer uptake and a more diffuse distribution pattern within the soma and larger dendrites than microglia (Fig. 5B) . To better show the G6 dendrimer's neuronal co-localization, we used a higher gain to process neuronal images. In the CA1 region, G6 dendrimers were internalized only in necrotic pyramidal neurons that have smaller and deformed cell bodies (Fig. 5B, magnified  images 1 and 2 ), but not in healthy neurons that have larger, rounded cell bodies (Fig. 5B, magnified image 3) . We did not observe obvious co-localization of G6 dendrimers in astrocytes (Fig. S6) .
Differences between microglia and neurons in terms of G6 dendrimer uptake quantity and intracellular distribution may be associated with different uptake mechanisms [38, 39] . In the presence of inflammation, the activated microglia/macrophages in the CNS take up nanoparticles that cross the BBB; this uptake is associated with increased phagocytosis by activated microglia/macrophages (i.e., receptor-mediated endocytosis) [40] [41] [42] . On the other hand, internalization of nanoparticles by neurons only has been reported in few studies [43, 44] . Although in vitro study on hippocampal neuron showed clathrin mediated pathway as a main internalization pathway for G4 PAMAM dendrimers with amine terminal function groups [45] , in vivo study of dendrimer uptake by neurons under pathological condition was rarely reported. In our model, hippocampal neurons receive a major glutamatergic input to hippocampus from the neurons in the entorhinal cortex (perforant pathway) [6, 35] and during ischemia-reperfusion are Table 1 The ratio of urine AUC to serum AUC indicates the decreased renal clearance rate for G6 dendrimers, compared with G4 dendrimers. likely to exhibit abnormally high firing rates. Under such pathologic conditions, G6 dendrimers in the brain parenchyma could be taken up as part of this process. Our observation that G6 dendrimers only localize within injured neurons, but not in adjacent healthy neurons is consistent with our hypotheses about the mechanisms of G6 dendrimer update, but further studies are needed to fully characterize them. G6 Dendrimers show reduced renal clearance and increased hepatic clearance.
The total quantity of dendrimers in major organs were estimated by multiplying organ weights by the dendrimer concentrations determined in the extracts from the organs (Fig. 6A, B) . In the kidney, G6 dendrimers were mostly localized in the cortex (20.6 μg/g), rather than in the medulla (3.6 μg/g), and accounted for approximately 1% of the total dose. Confocal microscopy indicated that G6 dendrimers were filtered by glomeruli and accumulated in the proximal tubules, where reabsorption occurred (Fig. 6C) . The liver and spleen had similar G6 dendrimer concentrations (data not shown), and after considering organ weight, the liver and spleen took up 1.5% and 0.5% of total dose, respectively (Fig. 6A) . The dendrimer distribution in the liver and spleen was further investigated by confocal microscopy. In liver, G6 dendrimers appeared in sinusoids and downstream in the central vein. In spleen, G6 dendrimers mostly were localized in the red pulps and the marginal zone around the white pulps: they did not penetrate into the white pulps. These observations indicate that the reticuloendothelial system (RES) might play a major role in hepatic and splenic dendrimer accumulation (Fig. 6C) . In total, about 3.3 ± 0.6% total dose remained in all major organs when the animal was sacrificed (72 h after HCA). The liver and the kidney accounted for most of the G6 dendrimer accumulation in major organs (~1.5% and 1% of overall ID, respectively), followed by spleen, lung, heart, and pancreas (Fig. S7) . At 72 h after HCA, we estimated that 80% of G6-Cy5 ID was cleared.
The distribution of G6 dendrimers differed from that of G4 dendrimers. According to our previous study in the canine model, G4 dendrimer concentration in the kidney was 26.3-fold and 54.6-fold higher than its concentration in the liver after 6 h or 48 h post i.v. injection, respectively. G4 dendrimers (~4.3 nm) were removed mainly through renal clearance and retained more in the kidney cortex after 48 h. In contrast, the concentration of G6 dendrimers in the kidney was only 4.5-fold higher than that in the liver under the current protocol (Fig. 6B) . This was also reflected in the fluorescence-based imaging of kidney tissue slices, where G4 dendrimers showed much higher intensity in the kidney tubules than G6 dendrimers (Fig. 6C) . Still, G6 dendrimers were partially excreted into urine, as evidenced by a rapid increase in urine dendrimer levels concordant with the administration time of dendrimers (peaked when infusion was finished and after second bolus dose; see Fig. S8 ). In this case, the ratio of AUC in urine to that in serum indicates the efficiency of renal clearance between the G6 and G4 dendrimers. During the first 5 h after the final bolus dose, this ratio was 3.69 for G4 dendrimers, while G6 dendrimers exhibited a much lower value (0.67). Moreover, the ratio was 3.77 and 0.57 for G4 dendrimers and G6 dendrimers during the entire monitored period respectively (Table 1 ). The decrease in ratios of AUC urine to AUC serum suggests a reduced renal clearance rate for G6 as compared to G4 dendrimers. We also observed a four-fold increase in the G6 dendrimer's concentration in the liver compared to G4 dendrimer at 48 h post the last dose ( Fig. 6B and Table 2 ), and enhanced liver and spleen uptake for G6 dendrimers (Fig. 6C) , indicating the decreased renal clearance rate was associated with increased RES system G6 dendrimer uptake. These results demonstrated that the increase in dendrimer size (4.3 nm to 6.7 nm) significantly impacted the rate of renal clearance, when dendrimer surface properties remain unchanged.
Generally, the renal filtration threshold is considered to be 6-8 nm [20] . For nanoparticles of this intermediate size, surface functionality plays a key role in determining elimination mechanisms [19] . In many instances, nanoparticles that do not interact with serum proteins (normally neutrally or negatively charged) tend to be removed through renal clearance if they are smaller than 6 nm, while nanoparticles larger than this size would generally be cleared through liver. This size-cutoff effect has been observed for dendrimers or inorganic nanomaterials such as gold nanoparticles, silica nanoparticles, quantum dots, or iron oxide nanoparticles [46] [47] [48] [49] [50] . Reportedly, nanoparticles~6 nm in size, categorized as the intermediate size within the transition range, could provide different pharmacokinetic outcomes. For instance, in a murine model, hydroxyl-terminated PAMAM dendrimers have been shown to exhibit relatively increased hepatic compared to renal accumulation when the generation increases from G5 (~4.6 nm) to G6 (~6.0 nm). This suggests hepatic clearance of nanoparticles at this size plays an important role [46] . This observation was also noted in another study, which found that 4.3 nm PEG 350 functionalized Au nanoclusters, 64 Cualloy were mainly cleared through both kidney filtration and the hepatic excretion routes [51] . However, other studies have reported conflicting results. One found that a 6.7 nm negatively charged gold nanoparticle was predominantly cleared in the kidney (~70% ID and b 5% ID underwent renal and feces excretion, respectively, after 72 h) [49] . Another biodistribution study in a mouse model found that 7 nm RGD-PEG functionalized silica nanoparticles were removed mainly through renal clearance (~72% ID excretion after 96 h) rather than RES clearance (~15% ID excretion after 96 h) [48] . Our results imply both renal/hepatic systems may participate in dendrimer clearance for the HCA canines, since G6 dendrimers mainly accumulates in the kidney and liver. These results reflect the representative pharmacokinetics of nanomedicine in similar large animal models. We believe that, taken together, our biodistribution results in a clinically relevant large animal model of a commonly used surgical technique will be highly relevant to the performance of PAMAM dendrimers in clinical trials.
Conclusions
In this study, we demonstrated that G6 PAMAM dendrimers with hydroxyl group-functionalized surface are better vehicles for targeting injured CNS cells in a 30 kg canine brain injury model than G4 dendrimers. G6 dendrimers showed greater brain accumulation and penetrating efficiency into CSF than many clinically used drugs, with CSF/serum ratios ranging between 0.02 and 0.2 throughout the experiment's duration. The G6 dendrimer's ability to penetrate the blood brain barrier was associated with the severity of inflammation, with higher dendrimer accumulation in the injured brain from animals having higher CSF levels of pro-inflammatory cytokines. Our results also Table 2 G4 and G6 dendrimer accumulation within injured brain regions and major organs in a canine model of HCA. In the G6 biodistribution study, animals underwent 1.5 h of HCA and dendrimers were given at a dose of 6 mg/kg (based on 30 kg animal weight, the total injection dose per animal is 180 mg). In the G4 biodistribution study, animals underwent 2.0 h of HCA and dendrimers were given at a dose of 5 mg/kg (based on 30 kg animal weight, the total injection dose per animal is 150 mg). suggest that G6 dendrimers specifically target microglia and injured neuronal cells, the major cell types associated with neuroinflammation and excitotoxicity. This suggests G6 dendrimers may be powerful vehicles to deliver potent drugs that attenuate these two major injury mechanisms. The relatively high dendrimer levels in the CNS may be attributed to an extended systemic circulation due to the size of G6 dendrimers, which lie in the intermediate range for glomerular filtration (6.7 nm). Dendrimers of such size avoid rapid renal or RES clearance as compared to smaller dendrimers, but are still small enough to penetrate an impaired BBB. This clinically relevant large animal model provides a conceptual framework for how dendrimer-based drug delivery systems may potentiate existing therapies and merits consideration as a translational model for future trials involving CNS pharmacotherapies.
